CME and CFTC Clash Over On-Chain Perpetual Futures

The conflict between the CME Group and the US Commodity Futures Trading Commission (CFTC) has escalated, with the CME suing the CFTC over its approval of on-chain perpetual futures products. The CME argues that these products, which allow users to speculate on asset prices with leverage and no expiration date, are harmful to its traditional futures products and that the CFTC's decision did not consider the ramifications. The CFTC, on the other hand, claims that its decision is aimed at allowing innovation and competition in the derivatives market. The dispute has significant implications for the US approach to the rapidly growing on-chain perpetual futures market, with non-US volume reportedly reaching $60 trillion last year. The CME's lawsuit challenges the CFTC's decision to allow the prediction markets platform Kalshi and cryptocurrency exchange Coinbase to list crypto perpetual futures, alleging that the regulator is mislabeling the products and misapplying the law. The CFTC's chairman, Mike Selig, has defended the decision, stating that the regulator is committed to allowing innovation and competition in the derivatives market. The dispute has sparked a heated debate, with some arguing that the CME is trying to stifle innovation and others claiming that the CFTC is not doing enough to regulate the market. The outcome of the lawsuit is likely to have significant implications for the future of on-chain perpetual futures in the US.